Accuray rolls out Helix to boost cancer treatment in India

Published - September 24, 2024 10:12 pm IST - MUMBAI

With rising cases of cancer in India, Accuray which is into radiation therapy, said it was stepping up to support cancer treatment with the introduction of Accuray Helix, a configuration of Radixact Treatment Delivery System in India.

“Accuray Helix brings flexibility and versatility and is intended to drive improvements in personalisation and patient care, while simultaneously facilitating treatment of more patients each day, boosting productivity for clinics and enabling them to efficiently manage the growing demand for cancer care,” the company said in a statement.

It allows healthcare providers to address a broad range of cancer types even in clinics in smaller cities. “Our vision is to expand the curative power of radiation therapy to improve as many lives as possible, no matter where they are located,” Xavier De Misouard, President & General Manager – EIMEA, Accuray said in a statement. 

“Accuray Helix is designed to bridge gaps in care access across countries like India. By providing advanced, fast, and precise treatments, we are enabling medical teams to reach more patients and help improve outcomes nationwide,” he added.  

Vidhi Prasad, Managing Director, India & Subcontinent, Accuray said, “We are actively working with healthcare providers all across India to deliver precision technology for cancer care. We strive to empower healthcare professionals to manage increased patient loads without compromising the quality of care, helping to ensure that no patient is left behind.”

Projections indicate a 12.8% increase in cancer cases by 2025 in India. Currently, India sees about 1.4 million new cancer cases annually, and this is expected to increase. It is estimated that 50-60% of patients with cancer will need radiotherapy.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.